Ambalal Sarabhai Enterprises Ltd Management Discussions

Overview of Indian Pharmaceutical Industry 2026

Introduction

The Indian pharmaceutical industry further reinforced its position as the "Pharmacy of the World" during FY 2025-26, with a market size of approximately USD 60.32 billion and ranking third globally by volume and eleventh by value. The sector is steadily evolving from a generic-focused industry to an innovation-driven pharmaceutical ecosystem, supported by favourable government policies, rising healthcare demand, and expanding global market opportunities. With an annual turnover of 4.72 lakh crore in FY25 and FDI inflows of

13,193 crore during FY 2025-26 (up to September 2025), the industry continues to attract strong investor interest. Further, the proposed Biopharma SHAKTI initiative is expected to strengthen Indias position as a global biopharmaceutical manufacturing hub and support the industrys long-term growth trajectory towards a projected market size of USD 130 billion by 2030.

Indias Position in the Global Pharmaceutical Market

India continues to be the worlds largest supplier of generic medicines, contributing nearly 20% of global generic drug supplies and manufacturing approximately 60,000 generic brands across 60 therapeutic categories. The country has established itself as a trusted source of affordable, high-quality medicines, supported by the highest number of USFDA-approved manufacturing facilities outside the United States and a strong API manufacturing base. India also plays a vital role in global healthcare through its leadership in vaccine production, supplying a significant share of global vaccine requirements and supporting immunization programmes worldwide. These strengths reinforce Indias position as a reliable and cost-effective pharmaceutical manufacturing hub.

Export Performance and Foreign Investment

Indias pharmaceutical exports have demonstrated

sustained growth over the years, reaching approximately USD 30.5 billion during FY 2024-25, compared to USD 1.9 billion in 2000-01. Indian pharmaceutical products are currently exported to over 190 countries, with nearly half of exports directed towards highly regulated markets such as the United States and Europe. The industry has also diversified its export footprint by expanding into emerging markets across Africa, Latin America, the Middle East, and Asia, thereby enhancing resilience against regional trade and tariff-related challenges. Alongside exports, increasing foreign direct investment continues to reflect strong global confidence in Indias manufacturing capabilities, regulatory framework, and long-term growth prospects.

Trade Agreements and Global Market Access

Indias expanding network of international trade agreements is expected to create additional growth opportunities for the pharmaceutical and medical device sectors. Recent trade agreements with the European Union, the United Kingdom, and New Zealand are expected to improve market access, reduce tariff barriers, and enhance the competitiveness of Indian pharmaceutical products in key global markets. The India-UK Comprehensive Economic and Trade Agreement (CETA) provides zero-duty access for several pharmaceutical products and medical devices, while the proposed India-EU Free Trade Agreement is expected to further strengthen export opportunities and integration into global healthcare value chains. Similarly, the India-New Zealand Free Trade Agreement is anticipated to facilitate greater pharmaceutical exports through improved tariff concessions.

Government Initiatives Supporting Growth

Government initiatives continue to play a significant role in strengthening the pharmaceutical sector. Production Linked Incentive (PLI) Schemes for pharmaceuticals, bulk drugs, and medical devices are supporting domestic manufacturing, reducing import dependence, and encouraging investments in critical healthcare infrastructure. These initiatives have contributed to reducing reliance on imported Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and Drug Intermediates (DIs), thereby enhancing supply chain resilience and promoting self-reliance in pharmaceutical manufacturing. Additional measures, including bulk drug parks, medical device parks, and research-driven programmes, are further supporting the industrys long-term competitiveness.

Outlook

The outlook for the Indian pharmaceutical industry remains positive, supported by strong domestic demand, expanding exports, increasing healthcare expenditure, regulatory credibility, and continued government support. Rising investments in manufacturing, innovation, quality systems, and research capabilities are expected to further strengthen Indias position in global pharmaceutical markets. With robust manufacturing infrastructure, growing international acceptance, supportive policy measures, and expanding global trade opportunities, the Indian pharmaceutical sector remains well-positioned for sustained growth, enhanced global engagement, and long-term resilience.

Electronics Industry Overview (2026)

The electronics industry in 2026 is being shaped by rapid advances in AI, semiconductor technology, sustainability, and smart connected devices. The market continues to grow, with AI acting as the biggest catalyst across consumer, industrial, automotive, and healthcare electronics.

Key Trends

* AI-powered electronics: Smartphones, PCs, cameras, instruments, wearables, and home appliances increasingly feature on-device AI for faster performance, better privacy, and lower cloud dependence.

* Semiconductor investment: Countries and companies are investing heavily in chip manufacturing to meet AI-driven demand and strengthen supply chains. Recent announcements from South Korea highlight multi-trillion-won investments in semiconductors and AI infrastructure.

* Automotive electronics: Electric vehicles, autonomous driving systems, and advanced driver assistance systems (ADAS) are driving demand for sensors, power electronics, and high-performance chips.

* Smart homes and IoT: Connected home devices continue to expand, with greater interoperability, energy efficiency, and AI-based automation.

* Wearables and digital health: Smartwatches and health-monitoring devices are evolving with advanced biometric tracking and medical-grade capabilities.

* Sustainability: Manufacturers are focusing on energy-efficient designs, recyclable materials, and resilient, regionalized supply chains.

Challenges

* Rising prices for memory chips and storage components due to AI infrastructure demand.

* Geopolitical tensions affecting semiconductor supply chains.

* Increasing cybersecurity and data privacy requirements.

* Shortage of skilled engineers in AI, embedded systems, and semiconductor design.

Emerging Technologies

* Edge AI and on-device intelligence

* Advanced packaging and chiplet architectures

* Wide-bandgap semiconductors (GaN and SiC)

* Humanoid robotics

* 6G research

* Spatial computing and smart glasses

* Next-generation display technologies such as RGB LED TVs.

Outlook

The electronics sector is expected to maintain strong growth through 2026 and beyond, driven by AI adoption, digital transformation, electrification of transportation, and increasing demand for smart, connected products. Companies that invest in innovation, resilient supply chains, and sustainable manufacturing are expected to be the strongest performers.